Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma
Business Wire•27/10/2026•06:45 ET
0
Key Highlights
- ➤MagnetisMM-32 met its primary PFS endpoint in 523-patient Phase 3 trial.
- ➤ELREXFIO reduced progression or death risk versus three standard regimens.
- ➤More than 75% of ELREXFIO patients remained progression-free at analysis.
- ➤Estimated 18-month PFS reached 68%, with median PFS not yet reached.
- ➤Grade 3-plus infections occurred in 27.5% with ELREXFIO versus 18.1% for controls.
Expert Statements
Jeff Legos, Chief Oncology Officer, Pfizer
“The treatment landscape for multiple myeloma continues to evolve as anti-CD38-based regimens and lenalidomide are increasingly used earlier in care. Yet many patients ultimately experience disease progression, with limited treatment options available following these commonly used therapies. MagnetisMM-32 demonstrates that ELREXFIO, an off-the-shelf, fixed-dose monotherapy, delivers a significant and clinically meaningful progression-free survival benefit and an encouraging safety profile in this increasingly important treatment setting, with median PFS not yet reached and a high percentage of patients remaining progression-free at the time of analysis. These findings further strengthen the rationale for moving BCMA-directed therapy earlier in the treatment journey and underscore ELREXFIO's potential to help redefine outcomes for patients.”
C. Ola Landgren, Professor of Medicine, Chief of Myeloma Division and Director of Sylvester Myeloma Institute, University of Miami Miller School of Medicine
“The MagnetisMM-32 results are particularly compelling given the rigorous and clinically relevant benchmark of three established standard-of-care regimens. Demonstrating a significant progression-free survival benefit against this active control highlights the potential of elranatamab-bcmm to provide an important treatment option for patients whose disease has progressed following anti-CD38 therapy and lenalidomide.”
Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma
In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for patients whose disease progressed after anti-CD38 therapy and lenalidomide, with median PFS not yet reached
Get started
Create a free account to read the full story.